Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice

Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899–910

Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J et al (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354:924–933

Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K et al (2010) Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 68(3):295–303

European Medicine Agency (2006) http://www.emea.europa.eu/humandocs/PDFs/EPAR/tysabri/H-603-en6.pdf

Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW et al (2006) Natalizumab plus interferon-β 1a for relapsing multiple sclerosis. N Engl J Med 354:911–923

The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45(7):1277–1285

Klawiter EC, Cross AH, Naismith RT (2009) The present efficacy of multiple sclerosis therapeutics: is the new 66 % just the old 33 %? Neurology 73(12):984–990

Lanzillo R, Quarantelli M, Bonavita S, Ventrella G, Lus G, Vacca G, Prinster A, Orefice G, Tedeschi G, Brescia Morra V (2011) Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study. Acta Neurol Scand. doi: 10.1111/j.1600-0404.2011.01622.x

Prosperini L, Giannì C, Leonardi L, De Giglio L, Borriello G, Galgani S, Pozzilli C, Gasperini C (2012) Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. Mult Scler 18(1):64–71 PubMed PMID: 21828195

Sangalli F, Moiola L, Bucello S, Annovazzi P, Rizzo A, Radaelli M et al (2011) Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study. Neurol Sci 31(3):299–302

Prosperini L, Borriello G, Fubelli F, Marinelli F, Pozzilli C (2011) Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome. Neurol Sci 31(Suppl 3):303–307

Castillo-Trivino T, Mowry EM, Gajofatto A, Chabas D, Crabtree-Hartman E, Cree BA et al (2011) Switching multiple sclerosis patients with breakthrough disease to second-line therapy. PLoS ONE 6(2):e16664

Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC et al (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227–231

McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121–127

Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46(4):907–911

Kappos L, Bates D, Hartung HP et al (2007) Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 6:431–441

Río J, Tintoré M, Sastre-Garriga J, Nos C, Castilló J, Tur C, Comabella M,Montalban X (2012) Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response. Eur J Neurol. doi: 10.1111/j.1468-1331.2011.03648.x . (Epub ahead of print)

Putzki N, Yaldizli O, Bühler R, Schwegler G, Curtius D, Tettenborn B (2010) Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland. Eur Neurol 63(2):101–106

Outteryck O, Ongagna JC, Zéphir H, Fleury MC, Lacour A, Blanc F et al (2010) Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. J Neurol 257(2):207–211

Belachew S, Phan-Ba R, Bartholomé E, Delvaux V, Hansen I, Calay P et al (2011) Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 18(2):240–245

Oturai AB, Koch-Henriksen N, Petersen T et al (2009) Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol 16:420–423